Despite positive clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from PBMs. The companies are often creating obstacles to https://kobiiqln540036.targetblogs.com/42334794/company-s-drug-faces-is-dealing-with-pharmacy-benefit-manager-obstacles-the-review-at-access-disputes